Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07353827CT.gov FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma | — | Not Yet Recruiting | — | — | — |
NCT06777628CT.gov Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05211323CT.gov A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT03058289CT.gov A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | — | Completed | — | — | — |
NCT01042041CT.gov Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | — | Completed | — | — | — |
NCT00875615CT.gov Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00276705CT.gov Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | — | Unknown | — | — | — |
NCT00183885CT.gov A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00003044CT.gov Chemotherapy in Treating Patients With Liver Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Sun Yat-sen University | P3 | BB · 64 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Adriamycin | Shanghai Zhongshan Hospital | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Jnj-54135419 | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Sufentanyl | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Tranexamic Acid | Konkuk University Medical Center | P4 | BB |
+42 more in the Liver Cancer cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →